Zacks: Analysts Expect NeuroDerm Ltd. (NDRM) Will Post Earnings of -$0.52 Per Share

Equities analysts forecast that NeuroDerm Ltd. (NASDAQ:NDRM) will post earnings of ($0.52) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for NeuroDerm’s earnings. The highest EPS estimate is ($0.42) and the lowest is ($0.58). NeuroDerm reported earnings of ($0.42) per share during the same quarter last year, which would suggest a negative year over year growth rate of 23.8%. The firm is expected to issue its next earnings report on Thursday, November 9th.

On average, analysts expect that NeuroDerm will report full-year earnings of ($2.06) per share for the current financial year, with EPS estimates ranging from ($2.26) to ($1.89). For the next fiscal year, analysts forecast that the business will report earnings of ($1.65) per share, with EPS estimates ranging from ($2.29) to ($0.18). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for NeuroDerm.

NDRM has been the topic of a number of recent research reports. Zacks Investment Research cut NeuroDerm from a “hold” rating to a “sell” rating in a research note on Saturday, July 15th. Deutsche Bank AG initiated coverage on NeuroDerm in a report on Friday, July 21st. They set a “buy” rating and a $47.00 price target on the stock. Raymond James Financial, Inc. downgraded NeuroDerm from an “outperform” rating to a “market perform” rating and set a $39.00 price target on the stock. in a report on Monday, July 24th. BidaskClub raised NeuroDerm from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. Finally, Roth Capital downgraded NeuroDerm from a “buy” rating to a “neutral” rating and upped their price target for the company from $33.00 to $39.00 in a report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $45.86.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://ledgergazette.com/2017/10/15/zacks-analysts-expect-neuroderm-ltd-ndrm-will-post-earnings-of-0-52-per-share.html.

Several large investors have recently made changes to their positions in the company. State Street Corp lifted its holdings in shares of NeuroDerm by 23.6% during the second quarter. State Street Corp now owns 58,378 shares of the biotechnology company’s stock valued at $1,746,000 after purchasing an additional 11,163 shares in the last quarter. DAFNA Capital Management LLC lifted its holdings in shares of NeuroDerm by 1.3% during the second quarter. DAFNA Capital Management LLC now owns 37,938 shares of the biotechnology company’s stock valued at $1,134,000 after purchasing an additional 500 shares in the last quarter. Nexthera Capital LP lifted its holdings in shares of NeuroDerm by 13.6% during the second quarter. Nexthera Capital LP now owns 327,240 shares of the biotechnology company’s stock valued at $9,784,000 after purchasing an additional 39,240 shares in the last quarter. ETF Managers Group LLC bought a new position in shares of NeuroDerm during the second quarter valued at $210,000. Finally, Balyasny Asset Management LLC lifted its holdings in shares of NeuroDerm by 156.5% during the second quarter. Balyasny Asset Management LLC now owns 110,800 shares of the biotechnology company’s stock valued at $3,313,000 after purchasing an additional 67,600 shares in the last quarter. 52.39% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NeuroDerm (NASDAQ:NDRM) remained flat at $38.90 during trading on Friday. 284,698 shares of the company’s stock were exchanged. NeuroDerm has a 1-year low of $15.20 and a 1-year high of $38.95. The stock’s 50 day moving average price is $38.81 and its 200 day moving average price is $31.79. The firm’s market capitalization is $1.02 billion.

About NeuroDerm

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.

Get a free copy of the Zacks researc

On average, analysts expect that NeuroDerm will report full-year earnings of ($2.06) per share for the current financial year, with EPS estimates ranging from ($2.26) to ($1.89). For the next fiscal year, analysts forecast that the business will report earnings of ($1.65) per share, with EPS estimates ranging from ($2.29) to ($0.18). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for NeuroDerm.

NDRM has been the topic of a number of recent research reports. Zacks Investment Research cut NeuroDerm from a “hold” rating to a “sell” rating in a research note on Saturday, July 15th. Deutsche Bank AG initiated coverage on NeuroDerm in a report on Friday, July 21st. They set a “buy” rating and a $47.00 price target on the stock. Raymond James Financial, Inc. downgraded NeuroDerm from an “outperform” rating to a “market perform” rating and set a $39.00 price target on the stock. in a report on Monday, July 24th. BidaskClub raised NeuroDerm from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. Finally, Roth Capital downgraded NeuroDerm from a “buy” rating to a “neutral” rating and upped their price target for the company from $33.00 to $39.00 in a report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $45.86.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://ledgergazette.com/2017/10/15/zacks-analysts-expect-neuroderm-ltd-ndrm-will-post-earnings-of-0-52-per-share.html.

Several large investors have recently made changes to their positions in the company. State Street Corp lifted its holdings in shares of NeuroDerm by 23.6% during the second quarter. State Street Corp now owns 58,378 shares of the biotechnology company’s stock valued at $1,746,000 after purchasing an additional 11,163 shares in the last quarter. DAFNA Capital Management LLC lifted its holdings in shares of NeuroDerm by 1.3% during the second quarter. DAFNA Capital Management LLC now owns 37,938 shares of the biotechnology company’s stock valued at $1,134,000 after purchasing an additional 500 shares in the last quarter. Nexthera Capital LP lifted its holdings in shares of NeuroDerm by 13.6% during the second quarter. Nexthera Capital LP now owns 327,240 shares of the biotechnology company’s stock valued at $9,784,000 after purchasing an additional 39,240 shares in the last quarter. ETF Managers Group LLC bought a new position in shares of NeuroDerm during the second quarter valued at $210,000. Finally, Balyasny Asset Management LLC lifted its holdings in shares of NeuroDerm by 156.5% during the second quarter. Balyasny Asset Management LLC now owns 110,800 shares of the biotechnology company’s stock valued at $3,313,000 after purchasing an additional 67,600 shares in the last quarter. 52.39% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NeuroDerm (NASDAQ:NDRM) remained flat at $38.90 during trading on Friday. 284,698 shares of the company’s stock were exchanged. NeuroDerm has a 1-year low of $15.20 and a 1-year high of $38.95. The stock’s 50 day moving average price is $38.81 and its 200 day moving average price is $31.79. The firm’s market capitalization is $1.02 billion.

About NeuroDerm

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.

Get a free copy of the Zacks research report on NeuroDerm (NDRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NeuroDerm (NASDAQ:NDRM)

Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply